Skip to content
Mozobil(plerixafor)
Mozobil (plerixafor) is a small molecule pharmaceutical. Plerixafor was first approved as Mozobil on 2008-12-15. It is used to treat multiple myeloma and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation, lymphoma, and multiple myeloma. The pharmaceutical is active against C-X-C chemokine receptor type 4. In addition, it is known to target C-C chemokine receptor type 4 and atypical chemokine receptor 3.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
therapeuticsD013812
operative surgical proceduresD013514
Trade Name
FDA
EMA
Mozobil
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Plerixafor
Tradename
Company
Number
Date
Products
MOZOBILSanofiN-022311 RX2008-12-15
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
mozobilNew Drug Application2020-08-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myelomaD009101C90.0
non-hodgkin lymphomaD008228C85.9
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Plerixafor, Mozobil, Genzyme
69871022023-07-22U-936
78975902023-07-22U-936
ATC Codes
L: Antineoplastic and immunomodulating agents
L03: Immunostimulants
L03A: Immunostimulants
L03AX: Other immunostimulants in atc
L03AX16: Plerixafor
HCPCS
Code
Description
J2562
Injection, plerixafor, 1 mg
Clinical
Clinical Trials
147 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.942131531
LymphomaD008223C85.915129
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.05224635
NeutropeniaD009503D702213
InfectionsD007239EFO_00005441212
WartsD014860B071212
AgammaglobulinemiaD000361D80.1111
TransplantationD01418011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.01412221
Hodgkin diseaseD006689C81311214
Myelodysplastic syndromesD009190D4657111
Sickle cell anemiaD000755EFO_0000697D57659
B-cell chronic lymphocytic leukemiaD015451C91.14429
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.02528
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003403417
Fanconi anemiaD005199Orphanet_84D61.09445
Healthy volunteers/patients325
GlioblastomaD005909EFO_0000515334
Show 37 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AstrocytomaD001254EFO_000027111
OligodendrogliomaD009837EFO_000063111
SarcomaD01250911
OsteosarcomaD01251611
End stage liver diseaseD058625EFO_1001311K72.111
Colorectal neoplasmsD01517911
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.911
Cystic fibrosisD003550EFO_0000390E8411
Pulmonary fibrosisD011658J84.1011
Myeloproliferative disordersD009196D47.111
Show 1 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphoma marginal zoneD018442C88.422
Hairy cell leukemiaD007943C91.422
Burkitt lymphomaD002051C83.722
Large-cell lymphoma immunoblasticD01640022
Extranodal nk-t-cell lymphomaD054391C86.011
Waldenstrom macroglobulinemiaD008258C88.011
Large-cell lymphoma anaplasticD017728C84.611
T-cell lymphoma peripheralD016411C84.911
Adult t-cell leukemia-lymphomaD015459C91.511
Large granular lymphocytic leukemiaD05406611
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePLERIXAFOR
INNplerixafor
Description
Plerixafor is an azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. It has a role as an immunological adjuvant, an antineoplastic agent, an anti-HIV agent and a C-X-C chemokine receptor type 4 antagonist. It is an azamacrocycle, a crown amine, a secondary amino compound, an azacycloalkane, a tertiary amino compound and a member of benzenes. It is functionally related to a 1,4,8,11-tetraazacyclotetradecane.
Classification
Small molecule
Drug classCXCR receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1
Identifiers
PDB
CAS-ID110078-46-1
RxCUI733003
ChEMBL IDCHEMBL18442
ChEBI ID
PubChem CID65015
DrugBankDB06809
UNII IDS915P5499N (ChemIDplus, GSRS)
Target
Agency Approved
CXCR4
CXCR4
Organism
Homo sapiens
Gene name
CXCR4
Gene synonyms
NCBI Gene ID
Protein name
C-X-C chemokine receptor type 4
Protein synonyms
CD184, CD184 antigen, chemokine (C-X-C motif) receptor 4, FB22, Fusin, HM89, LAP-3, LCR1, LESTR, Leukocyte-derived seven transmembrane domain receptor, Lipopolysaccharide-associated protein 3, LPS-associated protein 3, neuropeptide Y receptor Y3, neuropeptide Y3 receptor, NPYRL, SDF-1 receptor, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor
Uniprot ID
Mouse ortholog
Cxcr4 (12767)
C-X-C chemokine receptor type 4 (P70658)
Alternate
CCR4
CCR4
ACKR3
ACKR3
Organism
Homo sapiens
Gene name
CCR4
Gene synonyms
CMKBR4
NCBI Gene ID
Protein name
C-C chemokine receptor type 4
Protein synonyms
C-C CKR-4, CCR-4, CD194, chemokine (C-C motif) receptor 4, chemokine (C-C) receptor 4, K5-5
Uniprot ID
Mouse ortholog
Ccr4 (12773)
C-C chemokine receptor type 4 (Q14A03)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,515 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
122 adverse events reported
View more details